BioSpace News Archive

Vor Bio, a clinical-stage cell and genome engineering company, announced that it will participate in the following upcoming investor conferences.

Denali Therapeutics Inc. today announced interim results from Part A of a Phase 1/2 study evaluating TAK-594/DNL593 (PTV:PGRN) in healthy subjects.

DENTSPLY SIRONA Inc. announced the completion of the previously disclosed internal investigation into certain financial reporting matters.

A new study published in JAMA demonstrated that patients at high risk for acute kidney injury, the most common complication of percutaneous coronary intervention, had a significant reduction in AKI when cardiologists used Terumo Health Outcomes’ ePRISM clinical decision support platform.

Hummingbird Bioscience today announced that Chief Financial Officer Josh House and Chief Development Officer Leah DiMascio will participate in one-on-one investor meetings at the Credit Suisse 31st Annual Global Healthcare Conference on November 7 - 10, 2022 at the Terranea Resort in Rancho Palos Verdes, CA.

Dragonfly Therapeutics, Inc. (“Dragonfly”), today announced that the first patient has been dosed in a clinical trial being conducted by Merck, known as MSD outside the United States and Canada, to evaluate a solid tumor targeting TriNKET developed by Dragonfly.

KaliVir Immunotherapeutics, Inc. announced the appointment of Adina Pelusio, M.S., as Senior Vice President of Clinical Operations.

Insmed Incorporated today announced that management will present at the following investor conferences.

Blueprint Medicines (NASDAQ: BPMC) today announced its 2027 Blueprint to achieve precision medicine at scale, a five-year business strategy to expand the company’s reach to broader patient populations by leveraging its scientific leadership, proven development capability and integrated business.

Freenome announced 50 hospitals and community oncology practices across the United States have joined as clinical partners for its Vallania Study.